Search: (WFRF:(Fryknäs Mårten)) srt2:(2020-2024) >
Assessment in vitro...
-
Andersson, ClaesUppsala universitet,Cancerfarmakologi och beräkningsmedicin
(author)
Assessment in vitro of interactions between anti-cancer drugs and noncancer drugs commonly used by cancer patients
- Article/chapterEnglish2023
Publisher, publication year, extent ...
-
Lippincott Williams & Wilkins,2023
-
electronicrdacarrier
Numbers
-
LIBRIS-ID:oai:DiVA.org:uu-493151
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-493151URI
-
https://doi.org/10.1097/CAD.0000000000001344DOI
Supplementary language notes
-
Language:English
-
Summary in:English
Part of subdatabase
Classification
-
Subject category:ref swepub-contenttype
-
Subject category:art swepub-publicationtype
Notes
-
Cancer patients often suffer from cancer symptoms, treatment complications and concomitant diseases and are, therefore, often treated with several drugs in addition to anticancer drugs. Whether such drugs, here denoted as 'concomitant drugs', have anticancer effects or interact at the tumor cell level with the anticancer drugs is not very well known. The cytotoxic effects of nine concomitant drugs and their interactions with five anti-cancer drugs commonly used for the treatment of colorectal cancer were screened over broad ranges of drug concentrations in vitro in the human colon cancer cell line HCT116wt. Seven additional tyrosine kinase inhibitors were included to further evaluate key findings as were primary cultures of tumor cells from patients with colorectal cancer. Cytotoxic effects were evaluated using the fluorometric microculture cytotoxicity assay (FMCA) and interaction analysis was based on Bliss independent interaction analysis. Simvastatin and loperamide, included here as an opioid agonists, were found to have cytotoxic effects on their own at reasonably low concentrations whereas betamethasone, enalapril, ibuprofen, metformin, metoclopramide, metoprolol and paracetamol were inactive also at very high concentrations. Drug interactions ranged from antagonistic to synergistic over the concentrations tested with a more homogenous pattern of synergy between simvastatin and protein kinase inhibitors in HCT116wt cells. Commonly used concomitant drugs are mostly neither expected to have anticancer effects nor to interact significantly with anticancer drugs frequently used for the treatment of colorectal cancer.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
-
Ye, JiaweiUppsala universitet,Institutionen för medicinska vetenskaper,Southeast Univ, Sch Med, Dept Med Lab Sci, Nanjing, Peoples R China.
(author)
-
Blom, KristinUppsala universitet,Cancerfarmakologi och beräkningsmedicin(Swepub:uu)kribl842
(author)
-
Fryknäs, MårtenUppsala universitet,Cancerfarmakologi och beräkningsmedicin(Swepub:uu)mafry516
(author)
-
Larsson, RolfUppsala universitet,Cancerfarmakologi och beräkningsmedicin(Swepub:uu)rolflars
(author)
-
Nygren, PeterUppsala universitet,Cancerprecisionsmedicin(Swepub:uu)peterng
(author)
-
Uppsala universitetCancerfarmakologi och beräkningsmedicin
(creator_code:org_t)
Related titles
-
In:Anti-Cancer Drugs: Lippincott Williams & Wilkins34:1, s. 92-1020959-49731473-5741
Internet link
Find in a library
To the university's database